#PC3IatASCO : Improving comprehensive genotyping in patients with newly diagnosed non-squamous NSCLC. Abstract 362 Poster E5: meetings.asco.org/abstracts-pres…
Charu Aggarwal, MD, MPH Erica L. Carpenter, MBA, PhD Aditi Singh Lova Sun Megan Roy Corey Langer Melina Marmarelis #ASCOQLTY22

Thrilled to present results from our trial on a behavioral economic focused #Nudge intervention to implement #MolecularTesting at the time of new diagnosis of NSCLC. Check this and other interesting work being presented from Abramson Cancer Ctr. Penn Cancer Innovation Penn Precision Med #ASCOQLTY22

Amazing celebration tonight Abramson Cancer Ctr. as we toasted to Dr. David Vaughan’s book launch “Discovery and Healing” - 5 decades of hematology/oncology Penn Medicine - and I got a signed copy - that reads “to my Peloton pal:)” Cheers to David!
📕🥂🎉

2 days late…BUT the @penncancer #meso team is celebrating #meso theliomaday and hoping for continued progress for our patients!! Mesothelioma Applied Research Foundation Corey Langer

CM743 4y update: sustained OS benefit. No new signal by histology. No new tox signals #mesothelioma #ESMO22 BTOG

Incredibly excited to lead a Randomized Clinical Trial to formally assess the role of Telehealth to solve the problem of molecular under-genotyping in patients with #NSCLC

#PrecisionMedicine #Moonshot #TRACE

National Cancer Institute Penn Cancer Innovation Anil Vachani Kate Rendle, PhD (she/her) Penn Precision Med

This was a brilliant talk by Charles Swanton! A turning point in our understanding of the environmental contributions to lung cancer in never-smokers.
#LCSM

Had a wonderful time chatting about the progress and ongoing questions in mesothelioma with Stephen V Liu, MD and Sanjay Popat . What a treat to get to spend some time talking with these two! Mesothelioma Applied Research Foundation Abramson Cancer Ctr.

So proud of Kerry Reynolds and her amazing team Mass General Cancer Center for pioneering the IO complications inpt team 5 years ago. Has been the foundation on which multi-specialty expertise in IO tox has been built across our general hospital! #TrailBlazer #WIO 🙌science.org/content/articl…

#KRAS Pathway Alterations in Malignant Pleural Mesothelioma #MPM : An Underestimated Player.
KRAS pathway alterations are frequent in human MPM but have been likely underestimated by next generation sequencing #NGS studies.
mdpi.com/2072-6694/14/1…

Stay tuned for this upcoming episode of #LungCancerConsidered where I had the opportunity to chat about mesothelioma with Drs. Melina Marmarelis and Sanjay Popat. IASLC #MPM

2022-08-16 Updated chart of Biomarker-focused patient-caregiver groups. #LCSM The ROS1ders, Inc. ALKCancer Exon 20 Group, a multi-stakeholder organization EGFR Resisters RET Renegades ALKFusion KRASKickers NTRKers METCrusaders BrafBombers RETpositive

MET amp most common resistance mechanism within 1st yr post osi. Amps in ctdna hard to interpret but this tracks clinically. Best way to identify MET mech of resistance? I prefer IHC 2/2 ami/laz data, you? #WCLC22 @iaslc Stephen V Liu, MD H. Jack West, MD
Charu Aggarwal, MD, MPH

😂😂😂😂

This is an important stratification factor that should be reported in immunotherapy trials! #lcsm Abramson Cancer Ctr.